Guangzhou Yiming Kang Biotechnology

Guangzhou Yimingkang Biotechnology Co., Ltd. is a clinical-stage Chinese biotechnology company specializing in the development of innovative peptide therapeutics for inflammatory, autoimmune, and ophthalmic diseases. Founded in 2021 by Dr. Xia Xianmin, the company operates as an affiliate of Wuhan Yicheng Biotechnology. Its lead candidate is Epivotide (伊匹乌肽), a synthetic peptide that acts as a highly selective inhibitor of the p55PIK regulatory subunit of PI3K (PIK3R3). Epivotide is currently being evaluated in Phase 2 clinical trials for ophthalmic indications such as neurotrophic keratitis and dry eye syndrome, as well as perennial allergic rhinitis, with a nebulized inhalation formulation in early-stage development for respiratory inflammation.